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ABSTRACT
OpeningofBK-typeCa2C activatedKC channelsprotectstheheartagainstischemia-
reperfusion (IR) injury. However, the location of BK channels responsible for
cardioprotection is debated. Herein we conﬁrmed that openers of the SLO1 BK
channel, NS1619 and NS11021, were protective in a mouse perfused heart model of
IR injury. As anticipated, deletion of the Slo1 gene blocked this protection. However,
inanisolatedcardiomyocytemodelofIRinjury,protectionbyNS1619andNS11021
was insensitive to Slo1 deletion. These data suggest that protection in intact hearts
occurs by a non-cardiomyocyte autonomous, SLO1-dependent, mechanism. In this
regard, an in-situ assay of intrinsic cardiac neuronal function (tachycardic response
to nicotine) revealed that NS1619 preserved cardiac neurons following IR injury.
Furthermore, blockade of synaptic transmission by hexamethonium suppressed
cardioprotection by NS1619 in intact hearts. These results suggest that opening
SLO1 protects the heart during IR injury, via a mechanism that involves intrinsic
cardiacneurons.Cardiacneuronalionchannelsmaybeusefultherapeutictargetsfor
elicitingcardioprotection.
Subjects Biochemistry, Cardiology
Keywords Large conductance potassium channel, Ischemia, Reperfusion, Preconditioning,
Cardiac neurons, NS1619, NS11021
INTRODUCTION
All tissues, including the heart, possess endogenous mechanisms to protect against
ischemia-reperfusion (IR) injury, and the opening of KC channels is central to many
cardioprotectiveparadigmsincludingischemicpreconditioning(IPC)andanestheticpre-
conditioning (APC) (Facundo, Fornazari & Kowaltowski, 2006). The mitochondrial KATP
channel is perhaps the most widely associated with cardioprotection (O’Rourke, 2007;
Zoratti et al., 2009), but a large-conductance (BK) channel encoded by the Slo gene family
is also proposed to play a protective role in the heart (Bentzen et al., 2009; Wojtovich et al.,
2011). The Slo encoded channels comprise 3 isoforms (SLO1/2=3) (SalkoV et al., 2006),
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BK channel. PeerJ1:e48; DOI10.7717/peerj.48and although a channel resembling SLO1 (KCa1:1, KCNMA1) has been reported in
mitochondria (Siemen et al., 1999), gene deletion experiments show that Slo1 is not
requiredforcardioprotectionbyIPCorAPC(Wojtovichetal.,2011).
Despite ongoing debate regarding the identity of a mitochondrial BK channel, it is
widely reported that SLO1 is expressed in the heart (Chen et al., 2005; Jiang et al., 1999;
Tseng-Crank et al., 1994). Furthermore, SLO1 activation by small molecules such as
NS1619 and NS11021 is cardioprotective (Xu et al., 2002; Bentzen et al., 2007). SLO1 is
not found at the cardiomyocyte plasma membrane (Xu et al., 2002), but SLO1 channel
activity has been reported in intra-cardiac neurons (Franciolini et al., 2001) and Purkinje
ﬁbers (Callewaert, Vereecke & Carmeliet, 1986), where it is thought to play a role in
regulatingheartrate(Imlachetal.,2010).
Despite the assumption that NS1619 and NS11021 protect via a (mitochondrial)
SLO1 (Xu et al., 2002), many non-speciﬁc eVects such as opening of other ion
channels (Park et al., 2007; Saleh et al., 2007; Holland et al., 1996) and inhibition of
mitochondrial function (Aldakkak et al., 2010; Aon et al., 2010; Cancherini, Queliconi &
Kowaltowski, 2007; Debska et al., 2003; Kicinska & Szewczyk, 2004) have been reported
for these compounds, and a pharmaco-genomic study has not been conducted. Such
SLO1-independent eVects could underlie the cardioprotective beneﬁt of these com-
pounds (Cancherini, Queliconi & Kowaltowski, 2007; Kicinska & Szewczyk, 2004), and
herein we sought to investigate the contribution of SLO1 to the cardioprotection elicited
by NS1619 and NS11021, including studies in Slo1 =  mice to control for oV-target
eVects. We report on the discovery of a non-cardiomyocyte autonomous mechanism of
cardioprotectioninvolvingSLO1andintrinsiccardiacneurons.
MATERIALS & METHODS
Reagents, animals
NS11021 was a gift from Neurosearch A/S (Ballerup, Denmark). All other chemicals
were of the highest grade available from Sigma (St. Louis, MO) unless otherwise
speciﬁed. Slo1 =  .KCNMA1 = / mice were generated on the FVB background via
deletion of Exon1, which contains the translation start site and the S0 trans-membrane
segment (Meredith et al., 2004). This results in both transcripts and protein being
undetectable, and it has been previously shown that the lack of an S0 domain results in
anonfunctionalBKchannel (Zareietal.,2001;Zareietal.,2004).Animalsweregenotyped
by tail biopsy PCR, as previously described (Meredith et al., 2004). All experiments
used male WT and Slo1 =  littermates age 6–8 weeks. Mice were maintained in an
AAALAC-accredited pathogen-free barrier facility with food and water available ad
libitum. All procedures were in accordance with the NIH Guide for the Care and Use of
Laboratory Animals (2011 revision) and were approved by the University Committee on
AnimalResources.
Mouse Langendorff ex-vivo perfused heart
Following avertin anesthesia, a thoracotomy was performed, the aorta cannulated
in-situ and the heart rapidly transferred to perfusion apparatus as previously described
Wojtovich et al. (2013), PeerJ, DOI 10.7717/peerj.48 2/23(Wojtovichetal.,2011;Nadtochiyetal.,2009).TheheartwasperfusedwithKrebs-Henseleit
buVer in constant ﬂow mode (4 ml/min). The following experimental protocols were
observed: (i) IR injury: 20 min normoxic perfusion, 40 min global ischemia, 60 min
reperfusion. (ii) NS1619+IR: 10 min normoxic perfusion, 10 min of 5 M NS1619, 30 s
washout, then IR as above. (iii) NS11021+IR: 10 min normoxic perfusion, 10 min of
500nMNS11021,30swashout,thenIRasabove.
Studies involving hexamethonium were independently controlled and the following
experimental protocols were observed: (iv) IR injury: 25 min normoxic perfusion, 35 min
global ischemia, 60 min reperfusion. (v) NS1619+IR: 15 min normoxic perfusion, 10 min
of 5 M NS1619, 30 s washout, then IR as above. (vi) NS1619+IR+Hexamethonium:
12.5 min normoxic perfusion, 2.5 min of 500 M hexamethonium, 10 min of 5 M
NS1619 plus 500 M hexamethonium, 30 s washout of NS1619 only, 35 min global
ischemia, 5 min reperfusion plus 500 M hexamethonium, 55 min reperfusion.
(vii) Atpenin A5 (AA5)+IR: 5 min normoxic perfusion, 20 min of 10 nM AA5, 30 s
washout,thenIRasabove.(viii)AA5+IR+Hexamethonium:2.5minnormoxicperfusion,
2.5 minof500Mhexamethonium, 20min of10 nM AA5plus500Mhexamethonium,
30 s washout of AA5 only, 35 min global ischemia, 5 min reperfusion plus 500 M
hexamethonium, 55 min reperfusion. Note that diVerent ischemic times (35 vs. 40 min)
wereusedtoensureadequateindependentcontrolsforeverygroupexamined.
Toassessneuronalsurvival,heartswereexposedto100Mnicotinefor5minfollowing
the reperfusion period. Compounds were delivered via a syringe pump linked to an
injection port immediately above the perfusion cannula. The volume of added solutions
was 0.05% of the total perfusate volume. Following experimental protocols, hearts were
TTC stained and imaged as previously described to quantify infarct size (Wojtovich et al.,
2011;Nadtochiyetal.,2011).
Mouse cardiomyocyte isolation
Following avertin anesthesia, the aorta was cannulated in-situ and the heart rapidly
transferred to perfusion apparatus. The heart was perfused for 3 min with a modiﬁed
Krebs-Henseleit “buVer A” (118 mM NaCl, 4.7 mM KCl, 1.2 mM KH2PO4, 1.2 mM
MgSO4, 10 mM HEPES, 24 mM NaHCO3, 5.5 mM glucose, bubbled with 95% O2, 5%
CO2, pH 7.35, 37 C) at 3 ml/min to remove blood. The heart was then perfused with
digestion buVer (buVer A plus 0.25 mM CaCl2, 30 mM taurine, 10 mM 2,3-butanedione
monoxime, 0.0278% Trypsin, 25 mg collagenase A, 75 mg collagenase D) at 3 ml/min for
12 min. The heart was removed and teased apart with forceps. Tissue was dispersed with
10 ml stop buVer (buVer A plus 12:5 M CaCl2, 10% FBS) with a transfer pipette, then
passed through a 200 m ﬁlter. Myocytes were settled by gravity for 10 min, supernatant
removed, and pellet resuspended in 10 ml stop buVer. Ca2C was gradually increased from
12:5 M to 0.25 mM through four additions of CaCl2 over the course of 8 min. Myocytes
were settled by gravity for 10 min, supernatant removed, and pellet resuspended in 5 ml
normoxic buVer (buVer A plus 0.25 mM CaCl2, 10% FBS). Myocytes were counted and
Wojtovich et al. (2013), PeerJ, DOI 10.7717/peerj.48 3/23viabilitydeterminedbyTrypanblueexclusion.Onemousehearttypicallyyielded1:2106
cells(75%viable)andcellswereusedforsimulatedIRinjuryimmediatelyafterisolation.
Mouse cardiomyocyte simulated IR injury
Myocytes were equilibrated at a concentration of 105 cells/ml for 10 min in normoxic
buVer. Incubations were in 50 ml round-bottom tubes in a shaking water bath
(80 cycles/min) at 37 C. Myocytes were divided in to the following groups (i) Control,
100 min in normoxic buVer; (ii) Simulated ischemia-reperfusion (SIR), 10 min normoxic
buVer, then 1 h ischemia buVer (118 mM NaCl, 4.7 mM KCl, 1.2 mM KH2PO4, 1.2 mM
MgSO4,10mMHEPES,24mMNaHCO3,0.25mMCaCl2,10%FBS,gassedwith95%N2,
5%CO2,pH6.5,37 C),followedby30minnormoxicbuVer;(iii)DrugCSIR,comprising
treatment with compounds 10 min prior to SIR in normoxic buVer, then 1 h ischemia
buVer, 30 min normoxic buVer. Drugs tested (ﬁnal concentrations in parentheses) were:
NS1619 (5 M), NS11021 (500 nM) and diazoxide (10 M). Drugs were dissolved in
DMSOandthevehiclecomprised<0.1%oftotalincubationvolume.DMSOwasincluded
in the control and SIR groups at the appropriate times. To change buVers, cells were
centrifuged at 31  g for 2 min, and the pellet resuspended in the appropriate buVer.
Attheendofprotocols,viabilitywasdeterminedbyTrypanblueexclusion.
Isolated mitochondrial BK channel activity
Mitochondriawereisolatedfrom3mouseheartsaspreviouslydescribed (Wojtovichetal.,
2010).Themitochondriawereincubatedwith20MBTC-AMand0.05%PluronicF-127
for 10 min at room temperature. The ﬁnal mitochondrial pellet was suspended in 225 l
andstoredoniceuntiluse,within1.5hTlC uptakeintomitochondriawasmeasuredusing
a Varian Cary Eclipse spectroﬂuorimeter as previously described (Wojtovich et al., 2010)
bymonitoringchangesinBTCﬂuorescence(EX 488nm,EM 525nm).Whereindicated,
ATP(toblockmKATP channel),NScompounds(toopenmBKchannels)andpaxilline(to
blockBKchannels)werepresentatconcentrationsindicated.
Total heart histochemical acetylcholinesterase staining
Following IR protocols as described above, hearts were perfused with 10 mM phosphate
buVered saline (PBS; pH 7.4 at 25 C) for 3 min at 4 ml/min. Control hearts not exposed
to IR injury were cannulated and perfused with PBS. Hearts were then stained for acetyl-
cholinesterase (Rysevaite et al., 2011). Hearts were preﬁxed with 4% formalin for 30 min
at 4 C, then washed with PBS and incubated in PBS supplemented with hyaluronidase
(0.5mg/100ml)for18hat4 C.TheheartswerethenplacedinKarnovsky-Rootsmedium
(60 mM sodium acetate, 2 mM acetylthiocholine iodide, 15 mM sodium citrate, 3 mM
CuSO4, 0.5 mM K3Fe.CN/6, 0.1% trition-X 100, 0.5 mg/100 ml hyaluronidase, pH 5.6 at
4 C) for 3 h at 4 C. Following staining, hearts were kept in 10% formalin and visualized
underﬂuorescentilluminationusingGFPﬁltersonanOlympusMVXwideﬁelddissecting
microscope. Images were obtained using a PixeLink camera. The ﬂuorescent illumination
providedincreasedcontrastcomparedtovisiblelightwiththemonochromeCCD.
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Data presented are means  SEM. Statistical signiﬁcance (p < 0:05) between multiple
groups was determined using analysis of variance (ANOVA) with Bonferroni correction.
Mixed eVects models were generated using “R” software (R Development Core Team)
and the R packages lme4 (Bates & Maechler, 2009) and languageR (Baayen, 2008; Baayen,
2009). As ﬁxed eVects, we included treatment conditions, genotype, and their interaction
in the model. Normality and homogeneity were checked using visual inspections of plots
of residuals against ﬁtted values. Likelihood ratio tests comparing the models with ﬁxed
eVectstothenullmodelsusingonlyrandomeVects,wereusedtoassesstheaccuracyofthe
mixed eVects models. The model was further analyzed using pair wise comparison t-test.
WerejectedresultswherethemodelincludingﬁxedeVectsdidnotdiVersigniﬁcantlyfrom
thenullmodel.ForallmixedeVectsmodelswepresentMCMC-estimatedp-valuesthatare
consideredsigniﬁcantatthe < 0:05level.
RESULTS
Protection of intact hearts by NS1619 and NS11021 requires Slo1
Previously we showed that cardioprotection by both IPC and APC in intact hearts is
SLO1 independent (Wojtovich et al., 2011). However, the SLO1 openers NS1619 and
NS11021 are still reported to protect against IR injury in intact hearts (Bentzen et al.,
2009; Xu et al., 2002), suggesting that SLO1 alone can aVord protection. To examine the
pharmaco-genomics of SLO1, NS1619 and NS11021 in more detail, we utilized an ex-vivo
perfused heart model of IR injury. Representative raw data tracings of cardiac function
during IR injury are shown in Fig. 1. Hearts from WT and Slo1 =  mice exhibited
similar sensitivity to IR (quantitative data shown in Fig. 2), and as previously reported
both NS1619 and NS11021 protected the WT heart from IR injury (enhanced functional
recoveryandreducedinfarctsize),withNS11021being10-foldmorepotentthanNS1619.
As anticipated, protection was lost in Slo1 =  hearts, suggesting that SLO1 is a bona-ﬁde
target for the cardioprotective eVects of NS1619 and NS11021 in the intact heart. While
it is possible that SLO1 is merely a downstream mediator of protection by NS1619 and
NS11021,Occam’srazorwouldsuggestSLO1istheactualtarget.
Protection of isolated cardiomyocytes by NS1619 and NS11021 is
Slo1 independent
Slo1 mRNA is expressed at low levels in whole heart (Chen et al., 2005; Jiang et al., 1999;
Tseng-Crank et al., 1994), and it has been suggested that SLO1 is present in cardiomyocyte
mitochondria (Xu et al., 2002). We therefore hypothesized that SLO1 in cardiomyocyte
mitochondria may play a role in mediating the protective eVects of NS1619 and NS11021.
To test this hypothesis, adult mouse ventricular cardiomyocytes were isolated from WT
and Slo1 =  hearts and subjected to simulated IR injury. As expected, both NS1619 and
NS11021 elicited cytoprotection (reduced cell death) in response to IR (Fig. 3). However,
this protection was present in both WT and Slo1 =  derived myocytes, indicating it did
not require SLO1 activity. As a control, the mitochondrial KATP opener diazoxide was
Wojtovich et al. (2013), PeerJ, DOI 10.7717/peerj.48 5/23Figure 1 Representative left ventricular pressure traces from perfused hearts. Traces are shown for wild-type (WT) and Slo1 =  hearts, in the
presence of vehicle (Ctrl.), NS1619 or NS11021, as per the methods. Traces are compressed on the time (x) axis. The top and bottom boundaries
of the black shaded area represent the systolic and diastolic pressures, respectively. The onset of ischemia (I) and reperfusion (R) are indicated by
arrows. Scale bars on each trace represent 10 min. (x-axis) and 50 mmHg (y-axis).
protective in both WT and Slo1 =  cells. Overall these data suggest that the protection of
cardiomyocytes by NS1619 and NS11021 may be due to oV-target (non-SLO1) eVects of
these molecules, as reported elsewhere (Park et al., 2007; Saleh et al., 2007; Holland et al.,
1996; Aldakkak et al., 2010; Aon et al., 2010; Cancherini, Queliconi & Kowaltowski, 2007;
Debskaetal.,2003;Kicinska&Szewczyk,2004).
NS1619 and NS11021 exhibit Slo1 independent effects on isolated
mitochondria
TodirectlytestwhetherNS1619andNS11021wereabletoactivateBKchannelsinisolated
mitochondria, a modiﬁed thallium (TlC) ﬂux assay was utilized (Wojtovich et al., 2010).
As expected, both compounds were able to elicit a TlC ﬂux, in a manner sensitive to the
BK channel blocker paxilline (Fig. 4). However, this ﬂux was evident in mitochondria
derived from both WT and Slo1 =  hearts, indicating it did not originate at the level of
SLO1. Furthermore, bona ﬁde mitochondrial KC channels exhibit a slowing of TlC ﬂux
kinetics by increasing concentrations of KC and not NaC (since only KC competes for
TlC uptake). However, such competition was not seen for NS induced TlC ﬂux (data not
shown), suggesting it is not ion-speciﬁc. Together these data support the notion that NS
compounds have non-speciﬁc eVects on mitochondria. Such eVects may account for the
nonSlo1-dependentprotectionobservedinisolatedcardiomyocytes(Fig.3).
Wojtovich et al. (2013), PeerJ, DOI 10.7717/peerj.48 6/23Figure 2 SLO1 dependent protection of perfused mouse heart against ischemia-reperfusion (IR)
injury. Perfused FVB littermate WT (white symbols) and Slo1 =  (gray symbols) mouse hearts were
subjected to IR injury. Where indicated, hearts were treated with NS1619 (5 M) or NS11021 (500 nM)
priortoischemia.(A):Left-ventricularfunctionwasdeterminedasratepressureproduct(RPP;heartrate
 left ventricular developed pressure) and expressed as percent of initial value. Statistical signiﬁcance
between groups was determined using a mixed-eVects model. *p < 0:05 between NS11021 and control
(IR alone), #p < 0:05 between NS1619 and control (IR alone). (B): Following IR protocols, hearts
were sliced, stained with TTC and ﬁxed to delineate live (red) from dead or infarcted tissue (white).
Infarcts were quantiﬁed by planimetry and expressed as a percent of the area at risk (100% in this global
ischemia model). Images above the graph show representative slices from each group. Within each group,
individual values are on the left, and means  SEM on the right (N D 7 for IR group and 6 for all other
groups). *p < 0:05 between NS11021 and control (IR alone), #p < 0:05 between NS1619 and control (IR
alone).
Wojtovich et al. (2013), PeerJ, DOI 10.7717/peerj.48 7/23Figure 3 SLO1 independent protection of adult mouse cardiomyocytes against simulated ischemia-
reperfusion (IR) injury. Myocytes were isolated from adult littermate WT (white) and Slo1 =  (gray)
mouse hearts, and used immediately in the model of IR injury. Where indicated, cells were treated with
NS1619 (5 M), NS11021 (500 nM) or diazoxide (DZX, 10 M). Upon completion of the IR protocol,
cell viability was measured via Trypan blue exclusion and expressed as a percent of control (viability in
controlnormoxicgroupswas:WT703%,Slo1 =  694%).Experimentalconditionsarelistedbelow
the x-axis. Data are means  SEM, with N for each group listed in parentheses at the base oV each bar.
Each N represents an independent cardiomyocyte preparation. *p < 0:05 vs. IR alone (ANOVA).
SLO1 dependent protection in intact hearts requires cardiac neu-
ronal function
So far, our data show that SLO1 is not required for protection by NS1619 and NS11021
in isolated cardiomyocytes (Fig. 3), but is required for protection by these compounds in
the intact heart (Figs. 1 and 2). This suggests that in the intact heart, protection occurs
via SLO1 in a mechanism that is non-cardiomyocyte autonomous. Several non-myocyte
cardioprotectivemechanismsexist,includingremotepreconditioningwhichisthoughtto
compriseaneuronalsignalingcomponent(Hausenloy&Yellon,2008).Wethereforesought
to investigate a role for SLO1 in cardioprotection via non myocyte signaling, with a focus
on intrinsic cardiac neurons. Importantly, the ex-vivo heart preparation used herein is
denervated, such that surviving neurons are not central but rather they are intrinsic to the
heart.InadditionSLO1channelactivityhasbeendescribedincardiacneurons(Franciolini
et al., 2001) and Purkinje ﬁbers (Callewaert, Vereecke & Carmeliet, 1986), where it plays a
roleinregulatingheartrate(Wojtovichetal.,2011;Imlachetal.,2010).
Wojtovich et al. (2013), PeerJ, DOI 10.7717/peerj.48 8/23Figure 4 SLO1 independent KC channel activity in isolated mouse heart mitochondria. Mitochon-
dria were isolated from littermate WT (white) and Slo1 =  (gray) mouse hearts and loaded with
TlC-sensitive ﬂuorophore. Mitochondrial KC channel activity in the presence of NS compounds was
determined using the TlC-ﬂux assay. Data are (continued on next page...)
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presented as 1 ﬂuorescence upon TlC addition to media. ATP was present to block the mKATP channel.
The baseline 1 ﬂuorescence (Ctrl, set to 100%) was 24:7  2:3 and 24:9  4:4 arbitrary units in WT
(white bars) and Slo1 =  (gray bars), respectively. Experimental conditions are listed below the x-axis.
Data are means SEM, with N for each group listed in parentheses at the base oV each bar. Each N
represents an independent mitochondrial preparation. Control, ATP and ATPCPax data are replicated
betweenpanelsAandBforcomparison*p<0:05vs.ATP, †p<0:05vs.ATP+NScompound(ANOVA).
Figure 5 shows that blockade of neuronal function with the synaptic transmission in-
hibitorhexamethonium,preventedcardioprotection(reductionininfarctsize)byNS1619
in intact hearts. This eVect was speciﬁc to SLO1 and NS1619, since hexamethonium had
no eVect on protection aVorded by the mitochondrial KATP channel activator atpenin
A5 (Wojtovich & Brookes, 2009). These data also indicate that NS1619 protects via a
mechanismthatisdistinctfrommitochondrialKATP channelopening.
To further investigate the role of cardiac neurons in protection aVorded by SLO1
activators, we assessed neuronal status by histochemical staining for acetylcholinesterase
activity (AChE). No diVerences in AChE staining were found between control, IR, and
IRCNS1619 hearts, suggesting the acute time frame of IR injury in this model was not
suYcient to precipitate neuronal loss (Fig. 6A–C). We therefore hypothesized that a more
direct test of cardiac neuronal function might be necessary to assess neuronal protection
in this acute model. Hence, the response of heart rate to nicotine (which induces transient
tachycardia via nicotinic Ach receptors (Tosaka et al., 2003; Haass & Kubler, 1997)) was
measured after IR injury. As seen in Fig. 6D, no response to nicotine was seen in control
hearts subjected to IR, indicating loss of neuronal function. However, hearts protected
with NS1619 exhibited a robust post-IR nicotine response, and this eVect was blocked
by pre-treatment with hexamethonium, indicating a preservation of nicotine-sensitive
intrinsic cardiac neurons. Notably, hearts protected with the mKATP opener atpenin A5
did not exhibit a preserved nicotine response. This is consistent with the data in Fig. 4
showingthateventhoughatpeninA5wasprotective,thiscardioprotectionwasinsensitive
to hexamethonium. Overall these data indicate that both mKATP and SLO1 channels can
protect the heart (Figs. 1, 2 and 5), but they do so via distinct mechanisms, the latter
requiringcardiacneuronfunction.
DISCUSSION
Together, the current data suggest that the SLO1 openers NS1619 and NS11021 act to
preserve intrinsic cardiac neuronal function in IR injury, in a Slo1 dependent manner,
and this leads to protection of myocardium. As such, the function of cardiomyocytes in
IR injury can be preserved by activation of a non-cardiomyocyte-autonomous signaling
mechanism. From a pharmaco-genomic perspective, this is the ﬁrst study to show that
cardioprotection in the intact heart by the putative SLO1 activators NS1619 and NS11021
actuallyrequirestheSlo1geneproduct(Figs.1and2).
AlthoughthechemicalstructuresofNS1619andNS11021arequitediverse,aninactive
analog of NS11021 (NS13558) does not elicit cardioprotection (Bentzen et al., 2010),
suggesting these molecules bind to a speciﬁc target in the whole heart, presumably SLO1.
Wojtovich et al. (2013), PeerJ, DOI 10.7717/peerj.48 10/23Figure 5 Blocking cardiac neuronal function blocks SLO1 dependent protection in the intact
heart.(A,B):PerfusedFVBmouseheartsfromWTanimalsweresubjectedtoIRinjury.Whereindicated,
hearts were treated with NS1619 (5 M), atpenin A5 (AA5, 10 nM), or hexamethonium (Hex, 500 M)
as detailed in the methods. Left-ventricular function was determined as rate pressure product (RPP;
heart rate x left ventricular developed pressure) and expressed as a percent of initial value. Data are split
across two panels for clarity. Statistical signiﬁcance between groups was determined using a mixed-eVects
model. *p < 0:05 vs. IR alone, #p < 0:05 vs. NS1619 C IR. (C): Following IR protocols, hearts were
sliced, stained with TTC and ﬁxed to delineate live (red) from dead or infarcted tissue (white). Infarcts
were quantiﬁed by planimetry and expressed as a percent of the area at risk (100% in this global
ischemia model). Images above the graph show representative slices from each group. Within each group,
individual values are on the left, and means SEM on the right (N D 8 for IR, 7 for AA5CIR, and 6 for
all other groups). *p < 0:05 vs. IR alone, #p < 0:05 vs. NS1619CIR.
While the mitochondrial KATP channel would appear to be an obvious alternative target
for the NS compounds, protection by NS1619 is not blocked by the mKATP blocker
5-HD (Cao et al., 2005), suggesting this is not the case. Rather, the mechanism of
protection by SLO1 openers is distinct from that aVorded by activation of cardiac mKATP
Wojtovich et al. (2013), PeerJ, DOI 10.7717/peerj.48 11/23Figure 6 Histochemical staining and functional activity of cardiac neurons. Perfused FVB mouse
hearts from WT animals were subjected to IR injury. Where indicated, hearts were treated with NS1619
(5 M), atpenin A5 (AA5, 10 nM), hexamethonium (continued on next page...)
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(Hex,500M),orcombinationsofNS1619CHexorAA5CHex,asdetailedinthemethods.PanelsA–C
show representative total heart histochemical acetylcholinesterase (AChE) staining following (A) control
perfusion, (B) IR injury and (C) IR with NS1619 pre-treatment. Dorsal side of the heart is shown, with
magniﬁcations of boxed areas shown in right panels. (D): Functional activity of cardiac neurons was
determined following the six IR protocols used in Fig. 3, via the injection of nicotine (100 M) for 5 min.
The peak heart rate increase was found at 2 min, followed by desensitization and subsequent decrease in
heart rate. Data are means SEM. N for each group is shown in parentheses to the right of the legend.
Each N represents an individual perfused heart. *p < 0:05 vs. IR (ANOVA).
channels (e.g., by diazoxide or atpenin A5), and suggests that non-myocyte and possibly
non-mitochondrialKC channelsarealsoimportantindeterminingresponsestoischemia.
The data in Figs. 5 and 6 suggest that cardioprotection by SLO1 activators proceeds via
intrinsiccardiacneurons,withpreservationofneuronalfunctionduringIRinjuryleading
to improved cardiac functional recovery, decreased infarct size (Fig. 5), and the post-IR
ability to mount a tachycardic response to nicotine (Fig. 6D). This nicotine response
requiresbothintactcardiacneuronsandtheabilityofmyocytestorespondtoatachycardic
signal.Notably,heartsprotectedbymKATP agonistatpeninA5werefullycompetentatthe
contractile level post-IR (Fig. 5), but failed to respond to nicotine. This suggests a post-IR
defect in a non-cardiomyocyte cell-type, presumably neurons since this is the only other
cell type known to be involved in the nicotine response. Post-IR in NS1619 treated hearts
responded to nicotine in a manner that was blocked by hexamethonium (Fig. 6D), and
the preservation of contractile function by NS1619 was also blocked by hexamethonium
(Fig.5).
Overall, the most logical explanation for these data is that NS1619 protection proceeds
via SLO1 in cardiac neurons. However, we cannot rule out the possibility that NS1619
acts on other neuronal targets. Unfortunately this cannot be tested experimentally using
Slo1 =  mice, because post-IR Slo1 =  hearts treated with NS1619 are incompetent at
the contractile level (Figs. 1 and 2), so they cannot respond to nicotine anyway, regardless
of their neuronal status. Clearly, cardiomyocyte- or neuron-speciﬁc Slo1 =  animals
would be of enormous beneﬁt in further elucidating the protective mechanism of the NS
compoundsinfuture.
While a role for aVerent or eVerent neurons (or indeed residual synaptic bulbs from
central neurons) cannot be completely ruled out (Wenk & McCleskey, 2007), it should be
emphasized that the LangendorV perfused heart preparation is denervated upon removal
of the heart from the thorax, and thus the neurons of interest to this study are not aVerent
oreVerenttothecentralsystem,butareintrinsictotheheart.Thepresenceofganglionated
plexuses within the heart is well documented (Yuan et al., 1994), and a number of
importantsignalingroleshavebeenassignedtosuchneurons,includingcardiacresponses
to nitric oxide (Armour et al., 1995), endothelin (Armour, 1996), histamine (Armour,
1996), angiotensin II (Horackova & Armour, 1997), / adrenergic agonists (Armour,
1997), and nicotine (Murphy et al., 1994). Although the intrinsic cardiac neuronal system
has been proposed to play a role in cardiac responses to ischemia (Armour, 1999), the
currentstudyisamongtheﬁrsttodirectlydemonstratethisconcept.
Wojtovich et al. (2013), PeerJ, DOI 10.7717/peerj.48 13/23Figure 7 Working model of SLO1 (in)dependent mechanisms of action in NS1619/NS11021 cardio-
protection. (A): In isolated cardiomyocytes the NS compounds induce cardioprotection independent
of SLO1. The ‘target’ remains unclear but may include inhibition of respiration or the uncoupling of
oxidative phosphorylation (see text for details). This mechanism is compatible with the lack of evidence
for SLO1 in cardiomyocytes. (B): In the whole heart, cardioprotection by NS1619/NS11021 is dependent
on SLO1 and is likely mediated via a cell non-autonomous mechanism, involving intrinsic cardiac
neurons. A barrier is hypothesized to exist, possibly accounting for the inability of NS compounds to
recruit the nonspeciﬁc target responsible for protection in myocytes. This explains the lack of ability of
NS1619/NS11021 to protect the intact Slo1 =  heart. HEX D hexamethonium.
The activity of intrinsic cardiac neurons is increased during ischemia (Foreman et al.,
2000). Furthermore, SLO1 in neurons regulates neurotransmitter release (Wang et al.,
2001), and the loss of SLO1 results in an increased duration of release (Wang et al., 2001).
Thus, activating SLO1 with NS1619 or NS11021 may hyperpolarize neurons, limiting
neurotransmitter release and minimizing the neuronal depolarization and excitotoxicity
Wojtovich et al. (2013), PeerJ, DOI 10.7717/peerj.48 14/23associatedwithischemicevents(GribkoVetal.,2001).Insimpleterms,theNScompounds
may prevent excitotoxicity. The ability to modulate cardiac neuronal activity in this
manner is a promising therapeutic avenue for ischemic injury (Armour, 1999). Recently,
several non-myocyte cell types in the heart have emerged as key players in the response
to ischemic injury, including cardiac ﬁbroblasts (Kawaguchi et al., 2011), cardiac mast
cells (Reid et al., 2011; Koda et al., 2010), and cardiac stem/progenitor cells (Shah et al.,
2011).Atthisstage,itisnotclearwhetherthecardioprotectionobservedhereinrepresents
a direct eVect of cardiac neurons on cardiomyocytes, and the potential involvement of
additionalintermediarycelltypesintransmittingtheprotectivesignalcannotbeexcluded.
The precise sub-cellular location of SLO1 required for protection by NS1619 and
NS11021 remains unclear. Early work on the role of SLO1 in cardioprotection found
no expression on the surface of cardiomyocytes (Xu et al., 2002). When single-channel
recordings of a Ca2C-dependent KC channel were made in human glioma cell mito-
chondria (Siemen et al., 1999) a consensus emerged that the cardioprotective eVect of
SLO1 activators was likely due to a SLO1 channel in cardiomyocyte mitochondria (Xu
et al., 2002). Observations that the SLO channel blocker paxilline abrogates protection
by NS1619 and NS11021 (Bentzen et al., 2009; Xu et al., 2002), as well as the protection
aVorded by APC (Wojtovich et al., 2011), are often invoked as proof for the existence of
a “cardiac mitochondrial KCa channel”, and this naming convention is consistent with
the fact that mammalian SLO1 is a Ca2C sensitive isoform of SLO (SalkoV et al., 2006).
Further support comes from immunological studies, in which antibodies directed against
the canonical SLO1 (110–130 kDa) detect the protein in mitochondrial fractions (120, 80,
and55kDa)(Xuetal.,2002;Fretwell&Dickenson,2009;Wangetal.,2004;Singh,Stefani&
Toro,2012).
More recently however, the consensus view that SLO1 is a mitochondrial KCa channel
important for cardioprotection has been challenged by our observation that SLO1 is
dispensable for APC and IPC (Wojtovich et al., 2011). Furthermore, although the SLO
auxiliarysubunit4(Fretwell&Dickenson,2009;Piwonskaetal.,2008;Skalskaetal.,2009;
Ohya et al., 2005) has been found in mitochondria, this subunit renders SLO1 resistant to
charybdotoxin and iberiotoxin – toxins that block the eVects of NS1619 on mitochondria
(Meera, Wallner & Toro, 2000). We have also shown that in the model organism C.
elegans, the SLO2 isoform of the channel underlies both APC and mitochondrial KC
ﬂux (Wojtovich et al., 2011). While studies are ongoing to conﬁrm the identity of the
mitochondrial BK channel, it seems clear that the simple picture of a SLO1 channel in
cardiomyocyte mitochondria as the underlying mechanism of cardioprotection by APC
or NS compounds is untenable. Indeed, the data in Fig. 3 show that NS compounds
elicitedKC transportinisolatedmitochondriaindependentofSLO1,addingtothebodyof
evidenceforoV-targeteVectsofthesecompoundsatthemitochondriallevel.
Subsequently, the question arises as to the mechanism by which the SLO1 openers
NS1619 and NS11021 can elicit protection in isolated cardiomyocytes (Fretwell &
Dickenson, 2009; Chmielewska & Malinska, 2011), in a Slo1 independent manner (Fig. 3).
It seems reasonable to suggest that the well-documented oV-target eVects of these
Wojtovich et al. (2013), PeerJ, DOI 10.7717/peerj.48 15/23molecules (reinforced by data in Fig. 4) may underlie such protection (Aldakkak et al.,
2010;Cancherini,Queliconi&Kowaltowski,2007;Debskaetal.,2003;Kicinska&Szewczyk,
2004). Both NS1619 and NS11021 have been reported to inhibit respiration (Cancherini,
Queliconi & Kowaltowski, 2007; Kicinska & Szewczyk, 2004), promote mitochondrial
depolarization (Aon et al., 2010; Cancherini, Queliconi & Kowaltowski, 2007; Debska et
al., 2003; Kicinska & Szewczyk, 2004) and cause mitochondrial swelling independent
of KC (Cancherini, Queliconi & Kowaltowski, 2007; Bednarczyk, Barker & Halestrap,
2008) suggesting they can impact non-speciﬁc ion transport mechanisms (Aldakkak et
al., 2010; Cancherini, Queliconi & Kowaltowski, 2007). NS1619 has also been shown to
increase mitochondrial ROS generation without depolarization (Heinen et al., 2007), and
a role for small amounts of ROS in cardioprotective signaling is well known (Vanden
Hoek et al., 1998). Alternatively, NS1619 and NS11021 may protect cardiomyocytes via
non-mitochondrialtargetsthatremaintobeidentiﬁed.
Mitochondrial ion channels such as the mKATP and SLO2 remain important mediators
of IPC and APC cardioprotective signaling (Facundo, Fornazari & Kowaltowski, 2006;
Wojtovichetal.,2011;Murphy&Steenbergen,2007;Garlidetal.,2009;O’Rourke,2004),and
it should be emphasized that the data presented herein do not preclude the presence of a
SLO1 channel in the mitochondria. Slo1 has many splice variants (SalkoV et al., 2006) and
it is possible that such variants may be present in the mitochondrion, but these channels
are either not the primary target or lack the binding site necessary to respond to NS1619
and NS11021. Furthermore, the Slo1 =  mouse used in these studies has a deletion of
Exon1,whichencodestheS0domainrequiredforchannelfunction(Meredithetal.,2004;
Zarei et al., 2001; Zarei et al., 2004), making it unlikely that a functional splice variant
is present in the knockout. Further studies are needed to determine the nature of any
SLO1 in mitochondria, or to investigate the intriguing notion that SLO1 may reside in the
mitochondriaofintrinsiccardiacneurons.
A surprising paradox emerges when comparing the whole heart and cardiomyocyte
eVects of NS1619 and NS11021 (Figs. 2 and 3). Speciﬁcally, if these compounds are
capable of protecting isolated cardiomyocytes in a Slo1 independent manner, why is this
mechanism of protection not accessible in whole hearts? If it were, the compounds should
protect the Slo1 =  heart. One possibility may be the diVerent experimental systems, or
thattheisolatedmyocytesdoesnotexpressSLO1,whichmaypromotenonspeciﬁcactions
ofthesecompounds.Anotherpossibilityisthatabarrierexistsintheintactheart(possibly
a vascular diVusional barrier) which prevents NS1619 and NS11021 from activating the
protective pathway observed in cells. Notably, attempts to overcome this limitation by
using high concentrations of NS1619 (30 M) in the intact heart led to an exacerbation
of IR injury (data not shown), which may be related to reports that high concentrations
of this compound can depolarize mitochondria (Cancherini, Queliconi & Kowaltowski,
2007). Notably, a recent review article stated that “In whole heart experiments the eVective
concentration of NS1619 is actually lower due to limited diVusion of the drug to its site of
action, and thus, it promotes cardioprotection instead of mitochondrial damage and heart
stress.”(Singh,Stefani&Toro,2012)
Wojtovich et al. (2013), PeerJ, DOI 10.7717/peerj.48 16/23Clearly in the intact heart, something prevents NS1619 and NS11021 from protecting
myocytes directly, such that the only avenue of protection available to these molecules is
viaSLO1,andknockingoutthechannelabrogatesthisprotectivemechanism.Aschematic
outlining the diVerent actions of NS1619 and NS11021 in isolated myocytes vs. intact
hearts is shown in Fig. 7, with the exact nature of the protective signal initiated at the
cardiacneuronallevelbySLO1openersstilltobeelucidated.
In conclusion, the SLO1 channel is a cardioprotective target of NS1619 and NS11021,
and these molecules are important tools for assessing SLO1 function in the whole heart.
The molecules elicit protection in isolated cardiomyocytes that is independent of SLO1,
possibly mediated by oV-target eVects. In contrast at the whole heart level, protection by
NS1619 and NS11021 absolutely requires SLO1, and preserves intrinsic cardiac neuronal
function. Collectively these studies support the notion that intrinsic cardiac neurons are
important mediators of cardioprotection, and may be a therapeutic target (Hausenloy &
Yellon,2008).
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